CoChat
Sign Up
Cited by 5Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Latent classes of symptom trajectories among major depressive disorder patients in China

Wang, Yufei, Li, Jiarui, Bian, Wen, Duan, Yanping, Geng, Wenqi, Jiang, Jing, Zhao, Xiaohui, Li, Tao, Jiang, Yinan, Shi, Lili, Cao, Jinya, Zhu, Gang, Zhang, Kerang, Chen, Qiaoling, Tian, Hongjun, Wang, Xueyi, Zhang, Nan, Wang, Gang, Wei, Jing, Yu, Xin·2024·Journal of Affective Disorders
DOI 10.1016/j.jad.2024.01.144
Open this paper in CoChat — free account

Abstract

Objective This study aimed to understand the long-term symptom trajectories of Chinese patients with major depressive disorder (MDD) using piecewise latent growth modeling and growth mixture modeling. The investigation also aimed to identify the baseline characteristics indicative of poorer treatment outcomes. Methods A total of 558 outpatients with MDD were assessed using a sequence of surveys. The Hamilton Rating Scale for Depression (HRSD), Hamilton Anxiety Rating Scale (HAMA), and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) were used to evaluate baseline depression, anxiety, and cognitive function. Depression symptom severity was subsequently measured at the 1-month, 2-month, 6-month, 1-year, and 2-year follow-ups. Results Results indicated three depressive symptomology trajectories, including (a) severe, improving class (12.72 %), (b) partially responding, later deteriorating class (6.09 %), and (c) moderate, improving class (81.18 %). Logistic regression analyses showed that a history of cardiovascular disease (CVD) increased the odds of belonging to the partially responding, later deteriorating class, whereas higher baseline depression increased the odds of belonging to the severe, improving class compared to the moderate, improving class. Patients who experienced less depression relief during the first month of treatment had a lower probability of belonging to the moderate, improving class. Limitations Participant attrition in this study may have inflated the estimated rate of treatment-resistant patients. Conclusions The burden of CVD and poorer initial treatment response are plausible risk factors for poorer treatment outcomes, highlighting targets for intervention in Chinese MDD patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jad.2024.01.144

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Alexopoulos, 2001, “The depression–executive dysfunction syndrome of late life”: a specific target for D3 agonists?, Am. J. Geriatr. Psychiatry, 9, 22
  2. Alexopoulos, 2019, Mechanisms and treatment of late-life depression, Transl. Psychiatry, 9, 188, 10.1038/s41398-019-0514-6 · DOI · Paper page
  3. Bai, 2022, Trends in depression incidence in China, 1990–2019, J. Affect. Disord., 296, 291, 10.1016/j.jad.2021.09.084 · DOI
  4. Burdick, 2011, The MATRICS consensus cognitive battery in patients with bipolar I disorder, Neuropsychopharmacology, 36, 1587, 10.1038/npp.2011.36 · DOI
  5. Cuijpers, 2005, Examining differential effects of psychological treatment of depressive disorder: an application of trajectory analyses, J. Affect. Disord., 89, 137, 10.1016/j.jad.2005.09.001 · DOI
  6. Diallo, 2015, Power of latent growth curve models to detect piecewise linear trajectories, Struct. Equ. Model., 22, 449, 10.1080/10705511.2014.935678 · DOI
  7. Duan, 2021, Research on cognitive function in anxious depression patients in China, J. Affect. Disord., 280, 121, 10.1016/j.jad.2020.11.078 · DOI
  8. Forand, 2013, Pretreatment anxiety predicts patterns of change in cognitive behavioral therapy and medications for depression, J. Consult. Clin. Psychol., 81, 774, 10.1037/a0032985 · DOI
  9. Hamilton, 1959, The assessment of anxiety-states by rating, Br. J. Med. Psychol., 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  10. Hamilton, 1960, A rating scale for depression, J. Neurol. Neurosurg. Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  11. Hunot, 2007, A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences, Prim. Care Companion J. Clin. Psychiatry, 9, 91
  12. Iverson, 2011, Identifying a cognitive impairment subgroup in adults with mood disorders, J. Affect. Disord., 132, 360, 10.1016/j.jad.2011.03.001 · DOI · Paper page
  13. Judd, 2000, Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?, Am. J. Psychiatry, 157, 1501, 10.1176/appi.ajp.157.9.1501 · DOI · Paper page
  14. Kelley, 2018, Response rate profiles for major depressive disorder: characterizing early response and longitudinal nonresponse, Depress. Anxiety, 35, 992, 10.1002/da.22832 · DOI
  15. Liang, 2022, Self-compassion predicted joint trajectories of depression and anxiety symptoms during the COVID-19 pandemic: a five-wave longitudinal study on Chinese college students, J. Affect. Disord., 319, 589, 10.1016/j.jad.2022.09.078 · DOI
  16. Lin, 2021, Trajectories of depression in psychotherapy: how client characteristics predict clinical improvement, J. Clin. Psychol., 77, 1354, 10.1002/jclp.23119 · DOI
  17. Loo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study, Int. Clin. Psychopharmacol., 17, 239, 10.1097/00004850-200209000-00004 · DOI
  18. Lv, 2016, The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol, BMC Psychiatry, 16, 1, 10.1186/s12888-016-0953-z · DOI
  19. McDonald, 2002, Principles and practice in reporting structural equation analyses, Psychol. Methods, 7, 64, 10.1037/1082-989X.7.1.64 · DOI · Paper page
  20. McLennan, 2010, The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review, Int. J. Geriatr. Psychiatry, 25, 933, 10.1002/gps.2431 · DOI · Paper page
  21. Melfi, 1998, The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression, Arch. Gen. Psychiatry, 55, 1128, 10.1001/archpsyc.55.12.1128 · DOI · Paper page
  22. Muthén, 2000, Integrating person-centred and variable-centred analyses: growth mixture modelling with latent trajectory classes, Alcoholism, 24, 882, 10.1111/j.1530-0277.2000.tb02070.x · DOI
  23. Nylund, 2007, Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study, Struct. Equ. Model., 14, 535, 10.1080/10705510701575396 · DOI · Paper page
  24. Nylund-Gibson, 2016, Covariates and mixture modeling: results of a simulation study exploring the impact of misspecified effects on class enumeration, Struct. Equ. Model., 23, 782, 10.1080/10705511.2016.1221313 · DOI
  25. Palacio, 2016, Motivational interviewing improves medication adherence: a systematic review and meta-analysis, J. Gen. Intern. Med., 31, 929, 10.1007/s11606-016-3685-3 · DOI
  26. Papakostas, 2009, Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder, J. Clin. Psychiatry, 70
  27. Paykel, 1995, Residual symptoms after partial remission: an important outcome in depression, Psychol. Med., 25, 1171, 10.1017/S0033291700033146 · DOI · Paper page
  28. Ren, 2020, Burden of depression in China, 1990–2017: findings from the global burden of disease study 2017, J. Affect. Disord., 268, 95, 10.1016/j.jad.2020.03.011 · DOI · Paper page
  29. Scott, 2019, Trajectories of symptom change in the treatment for adolescents with depression study, J. Am. Acad. Child Adolesc. Psychiatry, 58, 319, 10.1016/j.jaac.2018.07.908 · DOI
  30. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J. Clin. Psychiatry, 59, 22
  31. Si, 2009, Evaluation of the reliability and validity of Chinese version of the mini-international neuropsychiatric interview in patients with mental disorders, Chin. Ment. Health J., 23, 493
  32. Smagula, 2015, Antidepressant response trajectories and associated clinical prognostic factors among older adults, JAMA Psychiatry, 72, 1021, 10.1001/jamapsychiatry.2015.1324 · DOI · Paper page
  33. Solomonov, 2021, Modifiable predictors of nonresponse to psychotherapies for late-life depression with executive dysfunction: a machine learning approach, Mol. Psychiatry, 26, 5190, 10.1038/s41380-020-0836-z · DOI
  34. Taylor, 2007, Rapid onset of true antidepressant action, Curr. Psychiatry Rep., 9, 475, 10.1007/s11920-007-0064-0 · DOI
  35. Taylor, 2013, The vascular depression hypothesis: mechanisms linking vascular disease with depression, Mol. Psychiatry, 18, 963, 10.1038/mp.2013.20 · DOI · Paper page
  36. Thase, 1992, Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment, Am. J. Psychiatry, 149, 1046, 10.1176/ajp.149.8.1046 · DOI · Paper page
  37. Trivedi, 2006, Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice, Am. J. Psychiatry, 163, 28, 10.1176/appi.ajp.163.1.28 · DOI · Paper page
  38. Ulvenes, 2022, A latent trajectory analysis of inpatient depression treatment, Psychotherapy, 59, 113, 10.1037/pst0000420 · DOI
  39. Van De Schoot, 2017, The GRoLTS-checklist: guidelines for reporting on latent trajectory studies, Struct. Equ. Model., 24, 451, 10.1080/10705511.2016.1247646 · DOI · Paper page
  40. Van Eeden, 2019, Severity, course trajectory, and within-person variability of individual symptoms in patients with major depressive disorder, Acta Psychiatr. Scand., 139, 194, 10.1111/acps.12987 · DOI
  41. Wang, 1999, Handbook of mental health assessment scale, Chin. Ment. Health J., 13, 220
  42. Xiang, 2019, Trajectories of major depression in middle-aged and older adults: a population-based study, Int. J. Geriatr. Psychiatry, 34, 1506, 10.1002/gps.5161 · DOI
  43. Zhao, 2021, Prevalence of major depressive disorder among adults in China: a systematic review and meta-analysis, Front. Psychol., 12

Cited by

Sorted by citations

Metadata

Authors
Wang, Y., Li, J., Bian, W., Duan, Y., Geng, W., Jiang, J., Zhao, X., Li, T., Jiang, Y., Shi, L., Cao, J., Zhu, G., Zhang, K., Chen, Q., Tian, H., Wang, X., Zhang, N., Wang, G., Wei, J., & Yu, X.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • First Hospital of China Medical University (CN)
  • Shanxi Medical University (CN)
  • Seventh People's Hospital of Dalian (CN)
  • Tianjin Anding Hospital (CN)
  • Hebei Medical University (CN)
  • Tianjin Medical University General Hospital (CN)
  • Capital Medical University (CN)
  • Peking University (CN)
Corresponding author
Wei, Jing
ORCID
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2024-04
Volume
350
Pages
746-754
ISSN
0165-0327 (ISSN-L)
DOI
10.1016/j.jad.2024.01.144
OpenAlex
W4391036752
Cited by
5
References
1
Citations by year
2026: 1 · 2025: 3 · 2024: 1
FWCI
1.42
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (T2341003)
  • National Key Research and Development Program of China (2013CB531305, 2021ZD0202001)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
major depressive disorder, symptom trajectories, treatment-resistant depression, cardiovascular disease, treatment response, cognitive function, anxiety, Chinese patients
MeSH terms
Anxiety, Anxiety Disorders, Cardiovascular Diseases, Depression, Depressive Disorder, Major, Major Depressive Disorder, Humans, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review